今村 道雄MICHIO IMAMURA

Last Updated :2021/05/31

所属・職名
病院(医) 講師
自己紹介
肝疾患全般、特に肝炎ウイルスの複製・増殖機能の解明、ウイルス性肝炎に対する有効な治療法開発を目的とした研究を行っています。肝炎ウイルスの増殖可能な培養細胞あるいは感染ウイルスの感染が可能となるヒト肝細胞を移植したマウス(ヒト肝細胞キメラマウス)を用いて、治療薬の探索や新規治療法の開発など臨床応用を目的としたトランスレーショナルリサーチを行っています。

基本情報

主な職歴

  • 1994年05月16日, 1995年09月30日, 広島大学, 医学部附属病院, 医員(研修医)
  • 1995年10月01日, 1996年03月31日, 県立広島病院, 臨床研修医
  • 1996年04月01日, 1999年03月31日, 庄原赤十字病院, 医師
  • 1999年04月01日, 2000年03月30日, 広島大学, 医学部附属病院, 医員
  • 2005年04月01日, 2005年04月30日, 広島大学, 病院, 医員
  • 2005年05月01日, 2007年03月31日, 広島大学, 病院, 助手
  • 2007年04月01日, 広島大学, 病院助教
  • 2015年08月01日, 広島大学, 病院, 講師

学歴

  • 広島大学, 医学系研究科, 日本, 2000年04月, 2005年02月
  • 宮崎大学, 医学部, 日本, 1987年04月, 1994年03月

学位

  • 博士(医学) (広島大学)

教育担当

  • 【学士課程】 医学部 : 医学科

担当主専攻プログラム

  • 医学プログラム

研究分野

  • 医歯薬学 / 内科系臨床医学 / 消化器内科学

研究キーワード

  • 肝炎ウイルス
  • 肝癌
  • 肝硬変

所属学会

  • 日本内科学会
  • 日本消化器内視鏡学会
  • 日本消化器病学会
  • 日本肝臓病学会

教育活動

授業担当

  1. 2021年, 学部専門, 通年, 器官・システム病態制御学I
  2. 2021年, 学部専門, 集中, 症候診断治療学

研究活動

学術論文(★は代表的な論文)

  1. Three-dimensional portography using multislice helical CT is clinically useful for management of gastric fundic varices, AMERICAN JOURNAL OF ROENTGENOLOGY, 176巻, 4号, pp. 899-905, APR 2001
  2. Balloon-occluded retrograde transvenous obliteration of gastric fundal varices with hemarrhage, American Journal of Roentgenology, 178巻, pp. 1167-1174, 20020501
  3. Combination of transcatheter arterial chemoembolization using cisplatin-lipiodol suspension and percutaneous ethanol injection for treatment of advanced small hepatocellular carcinoma., Am J Surg., 184巻, 3号, pp. 284-290, 20020901
  4. Suppression of macrophage infillltraction inhibits activation of hepatic stellate cells and liver fibrogenesis in rats., Gastroenterology, 128巻, pp. 138-146, 20050101
  5. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus., HEPATOLOGY, 42巻, 5号, pp. 1046-1054, 20051101
  6. G to A hypermutation of hepatitis B virus., Hepatology, 41巻, pp. 626-633, 20050301
  7. Emergence of a novel lamivudine-resistant hepatitis B virus variant with a substitution outside the YMDD motif., Antimicrob agents chemother, 50巻, 11号, pp. 3867-3874, 20061101
  8. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma., World J Gastroenterol., 13巻, 40号, pp. 5343-5350, 20070901
  9. Successful treatment of an entecavir-resistant hepatitis B virus variant, JOURNAL OF MEDICAL VIROLOGY, 79巻, 12号, pp. 1811-1817, DEC 2007
  10. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon, FEBS LETTERS, 581巻, 10号, pp. 1983-1987, MAY 15 2007
  11. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine, HEPATOLOGY, 45巻, 5号, pp. 1179-1186, MAY 2007
  12. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin, INTERVIROLOGY, 50巻, 6号, pp. 439-446, 2007
  13. Low serum level of hepatitis B indicates unlikely reactivation core-related antigen of hepatitis after cessation of lamivudine therapy, HEPATOLOGY RESEARCH, 37巻, 8号, pp. 661-666, AUG 2007
  14. Low-dose intermittent interferon-alpha therapy for HCV-related liver cirrhosis after curative treatment of hepatocellular carcinoma, WORLD JOURNAL OF GASTROENTEROLOGY, 13巻, 39号, pp. 5188-5195, OCT 21 2007
  15. Balloon-occluded retrograde transvenous obliteration for portal-systemic encephalopathy due to superior mesenteric-caval shunt via the right gonadal vein, INTERNAL MEDICINE, 46巻, 17号, pp. 1479-1480, 2007
  16. The long-term outcome of patients with bleeding gastric varices after balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY, 42巻, 8号, pp. 663-672, AUG 2007
  17. Dual effect of APOBEC3G on Hepatitis B virus, JOURNAL OF GENERAL VIROLOGY, 88巻, pp. 432-440, FEB 2007
  18. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo., Chin Med J (Engl)., 120巻, 10号, pp. 898-904, 20070601
  19. Dual effect of APOBEC3G on Hepatitis B virus., J Gen Virol., 88巻, pt2号, pp. 432-440, 20070101
  20. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF GASTROENTEROLOGY, 43巻, 7号, pp. 550-557, JUL 2008
  21. Etiology and outcome of acute liver failure: Retrospective analysis of 50 patients treated at a single center, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23巻, 8号, pp. 1216-1222, AUG 2008
  22. Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 89巻, pp. 2108-2113, SEP 2008
  23. Eicosapentaenoic acid could permit maintenance of the original ribavirin dose in chronic hepatitis C virus patients during the first 12 weeks of combination therapy with pegylated interferon-alpha and ribavirin. A prospective randomized controlled trial., Intervirology., 50巻, 6号, pp. 439-446, 20080201
  24. A Case of Fulminant Hepatic Failure Caused by Hepatitis E virus79117, Clinical Journal of gastroenterology, 1巻, pp. 69-74, 20080603
  25. Prospective study of short-term peginterferon-alpha-2a monotherapy in patients who had a virological response at 2 weeks after initiation of interferon therapy, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 23巻, 4号, pp. 541-545, APR 2008
  26. Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry, GASTROENTEROLOGY, 137巻, 2号, pp. 673-681, AUG 2009
  27. Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: A randomized clinical trial, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 24巻, 3号, pp. 366-371, MAR 2009
  28. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness, TRANSPLANT INTERNATIONAL, 22巻, 8号, pp. 805-813, AUG 2009
  29. Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection, HEPATOLOGY RESEARCH, 39巻, 12号, pp. 1159-1168, DEC 2009
  30. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice, JOURNAL OF CLINICAL INVESTIGATION, 119巻, 11号, pp. 3226-3235, NOV 2009
  31. Randomized Trial of High-Dose Interferon-alpha-2b Combined With Ribavirin in Patients With Chronic Hepatitis C: Correlation Between Amino Acid Substitutions in the Core/NS5A Region and Virological Response to Interferon Therapy, JOURNAL OF MEDICAL VIROLOGY, 81巻, 4号, pp. 640-649, APR 2009
  32. The first Japanese case of COACH syndrome, HEPATOLOGY RESEARCH, 39巻, 3号, pp. 318-323, MAR 2009
  33. Absence of viral interference and different susceptibility to interferon between hepatitis B virus and hepatitis C virus in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 51巻, 6号, pp. 1046-1054, DEC 2009
  34. G-to-A Hypermutation in Hepatitis B Virus (HBV) and Clinical Course of Patients with Chronic HBV Infection, JOURNAL OF INFECTIOUS DISEASES, 199巻, 11号, pp. 1599-1607, JUN 1 2009
  35. Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants, VIROLOGY, 405巻, 2号, pp. 361-369, SEP 30 2010
  36. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor, JOURNAL OF GENERAL VIROLOGY, 91巻, pp. 1668-1677, JUL 2010
  37. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice, JOURNAL OF GENERAL VIROLOGY, 91巻, pp. 1854-1864, JUL 2010
  38. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients, JOURNAL OF HEPATOLOGY, 53巻, 3号, pp. 439-443, SEP 2010
  39. three-dimensional portography using multislice helical ct is clinically useful for management of gastric fundic varices, American Journal of Roentgenology, 176巻, pp. 899-905, 20010601
  40. Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice., J Clin Invest., 119巻, 1号, pp. 3226-3235, 20091001
  41. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness., Transpl Int., 22巻, 8号, pp. 805-813, 20090801
  42. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients., J Hepatol., 53巻, 3号, pp. 439-443, 20100901
  43. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor., J Gen Virol., 91巻, 7号, pp. 1668-1677, 20100901
  44. Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 54巻, 8号, pp. 3205-3211, AUG 2010
  45. Prolongation of interferon therapy for recurrent hepatitis C after living donor liver transplantation: analysis of predictive factors of sustained virological response, including amino acid sequence of the core and NS5A regions of hepatitis C virus., Scand J Gastroenterol., 45巻, 12号, pp. 1488-1496, 20100701
  46. Amino acid substitutions in core and NS5A regions of the HCV genome can predict virological decrease with pegylated interferon plus ribavirin therapy, ANTIVIRAL THERAPY, 15巻, 8号, pp. 1087-1097, 2010
  47. Evaluation of portosystemic collaterals by MDCT-MPR imaging for management of hemorrhagic esophageal varices, EUROPEAN JOURNAL OF RADIOLOGY, 76巻, 2号, pp. 239-245, NOV 2010
  48. Animal model for study of human hepatitis viruses., 26巻, 1号, pp. 13-8, 20110101
  49. Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants., Virology., 405巻, 2号, pp. 361-369, 20100701
  50. Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B., Antimicrob Agents Chemother., 54巻, 8号, pp. 3205-3211, 20100801
  51. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones., Virology., 407巻, 1号, pp. 80-90, 20100801
  52. ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo, JOURNAL OF HEPATOLOGY, 55巻, 1号, pp. 11-18, JUL 2011
  53. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy., J Hepatol., 54巻, 6号, pp. 1094-1101, 20100501
  54. HBx protein is indispensable for development of viraemia in human hepatocyte chimeric mice., J Gen Virol., 91巻, 17号, pp. 1854-1864, 20100701
  55. Inverse Association of IL28B Genotype and Liver mRNA Expression of Genes Promoting or Suppressing Antiviral State, JOURNAL OF MEDICAL VIROLOGY, 83巻, 9号, pp. 1597-1607, SEP 2011
  56. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 1048-1057, JUN 2011
  57. Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice, JOURNAL OF HEPATOLOGY, 54巻, 5号, pp. 872-878, MAY 2011
  58. Animal model for study of human hepatitis viruses., J Gastroenterol Hepatol., 26巻, 1号, pp. 13-18, 20110101
  59. Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b., J Med Virol., 83巻, 6号, pp. 981-988, 20110601
  60. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus, HEPATOLOGY RESEARCH, 41巻, 11号, pp. 1046-1056, NOV 2011
  61. Effects of Hepatitis B Virus Infection on the Interferon Response in Immunodeficient Human Hepatocyte Chimeric Mice, JOURNAL OF INFECTIOUS DISEASES, 204巻, 2号, pp. 224-228, JUL 15 2011
  62. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy., Gut., 60巻, 2号, pp. 261-267, 20110201
  63. Hepatitis C Virus Infection Suppresses the Interferon Response in the Liver of the Human Hepatocyte Chimeric Mouse, PLOS ONE, 6巻, 8号, AUG 23 2011
  64. Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus., Hepatology., 54巻, 3号, pp. 764-771, 20110701
  65. Impact of Viral Amino Acid Substitutions and Host Interleukin-28B Polymorphism on Replication and Susceptibility to Interferon of Hepatitis C Virus, HEPATOLOGY, 54巻, 3号, pp. 764-771, SEP 2011
  66. Rapid Emergence of Telaprevir Resistant Hepatitis C Virus Strain from Wildtype Clone In Vivo, HEPATOLOGY, 54巻, 3号, pp. 781-788, SEP 2011
  67. Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region, HEPATOLOGY RESEARCH, 41巻, 11号, pp. 1126-1131, NOV 2011
  68. IL-28B predicts response to chronic hepatitis C therapy - fine-mapping and replication study in Asian populations, JOURNAL OF GENERAL VIROLOGY, 92巻, pp. 1071-1081, MAY 2011
  69. IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy, JOURNAL OF HEPATOLOGY, 54巻, 6号, pp. 1094-1101, JUN 2011
  70. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b, JOURNAL OF HEPATOLOGY, 54巻, 3号, pp. 408-414, MAR 2011
  71. Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy, JOURNAL OF GASTROENTEROLOGY, 46巻, 6号, pp. 799-808, JUN 2011
  72. Effects of hepatitis B virus infection on the interferon response in immunodeficient human hepatocyte chimeric mice., J Infect Dis., 204巻, 2号, pp. 224-228, 20110701
  73. In Vivo Adaptation of Hepatitis C Virus in Chimpanzees for Efficient Virus Production and Evasion of Apoptosis, HEPATOLOGY, 54巻, 2号, pp. 425-433, AUG 2011
  74. Prediction of Response to Peginterferon-Alfa-2b Plus Ribavirin Therapy in Japanese Patients Infected With Hepatitis C Virus Genotype 1b, JOURNAL OF MEDICAL VIROLOGY, 83巻, 6号, pp. 981-988, JUN 2011
  75. Hepatitis C virus infection suppresses the interferon response in the liver of the human hepatocyte chimeric mouse., PLoS One., 6巻, 8号, pp. e23856, 20110901
  76. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma, JOURNAL OF VIRAL HEPATITIS, 18巻, 10号, pp. E550-E560, OCT 2011
  77. IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients, JOURNAL OF GASTROENTEROLOGY, 47巻, 7号, pp. 834-844, JUL 2012
  78. Severe necroinflammatory reaction caused by natural killer cell-mediated Fas/Fas ligand interaction and dendritic cells in human hepatocyte chimeric mouse, HEPATOLOGY, 56巻, 2号, pp. 555-566, AUG 2012
  79. Hepatitis B Virus-Specific miRNAs and Argonaute2 Play a Role in the Viral Life Cycle, PLOS ONE, 7巻, 10号, OCT 16 2012
  80. Serum PAI-1 is a novel predictor for response to pegylated interferon-a-2b plus ribavirin therapy in chronic hepatitis C virus infection, JOURNAL OF VIRAL HEPATITIS, 19巻, 2号, pp. E126-E133, FEB 2012
  81. Recent trend of clinical features in patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 42巻, 4号, pp. 368-375, APR 2012
  82. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 27巻, 9号, pp. 1467-1472, SEP 2012
  83. Impact of interleukin-28B genotype on in vitro and in vivo systems of hepatitis C virus replication, HEPATOLOGY RESEARCH, 42巻, 9号, pp. 841-853, SEP 2012
  84. Identification of novel HCV deletion mutants in chronic hepatitis C patients, ANTIVIRAL THERAPY, 17巻, 8号, pp. 1551-1561, 2012
  85. ★, Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor, NATURE MEDICINE, 18巻, 2号, pp. 281-285, FEB 2012
  86. Achievement of Sustained Viral Response after Switching Treatment from Pegylated Interferon alpha-2b to alpha-2a and Ribavirin in Patients with Recurrence of Hepatitis C Virus Genotype 1 Infection after Liver Transplantation: A Case Report, INTERVIROLOGY, 55巻, 4号, pp. 306-310, 2012
  87. Genetics of IL28B and HCV-response to infection and treatment, NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 9巻, 7号, pp. 406-417, JUL 2012
  88. Circulating microRNA-22 correlates with microRNA-122 and represents viral replication and liver injury in patients with chronic hepatitis B, JOURNAL OF MEDICAL VIROLOGY, 85巻, 5号, pp. 789-798, MAY 2013
  89. Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients, JOURNAL OF GASTROENTEROLOGY, 48巻, 10号, pp. 1188-1204, OCT 2013
  90. Risk factors for the exacerbation of esophageal varices or portosystemic encephalopathy after sustained virological response with IFN therapy for HCV-related compensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 48巻, 7号, pp. 847-855, JUL 2013
  91. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice, GUT, 62巻, 7号, pp. 1055-1061, JUL 2013
  92. A novel TK-NOG based humanized mouse model for the study of HBV and HCV infections, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 441巻, 1号, pp. 230-235, NOV 8 2013
  93. Thromboxane A(2) Synthase Inhibitors Prevent Production of Infectious Hepatitis C Virus in Mice With Humanized Livers, GASTROENTEROLOGY, 145巻, 3号, pp. 658-+, SEP 2013
  94. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases, HEPATOLOGY RESEARCH, 43巻, 11号, pp. 1182-1189, NOV 2013
  95. A Translational Study of Resistance Emergence Using Sequential Direct-Acting Antiviral Agents for Hepatitis C Using Ultra-Deep Sequencing, AMERICAN JOURNAL OF GASTROENTEROLOGY, 108巻, 9号, pp. 1464-1472, SEP 2013
  96. HLA-DQB1*03 Confers Susceptibility to Chronic Hepatitis C in Japanese: A Genome-Wide Association Study, PLOS ONE, 8巻, 12号, DEC 20 2013
  97. Long-term outcome of patients with gastric varices treated by balloon-occluded retrograde transvenous obliteration, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 29巻, 5号, pp. 1035-1042, MAY 2014
  98. Long-Term Elimination of Hepatitis C Virus from Human Hepatocyte Chimeric Mice After Interferon-gamma Gene Transfer, HUMAN GENE THERAPY CLINICAL DEVELOPMENT, 25巻, 1号, pp. 28-39, MAR 1 2014
  99. Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 49巻, 12号, pp. 1548-1556, DEC 2014
  100. Ultradeep Sequencing Study of Chronic Hepatitis C Virus Genotype 1 Infection in Patients Treated with Daclatasvir, Peginterferon, and Ribavirin, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 58巻, 4号, pp. 2105-2112, APR 2014
  101. Two patients treated with pegylated interferon/ribavirin/telaprevir triple therapy for recurrent hepatitis C after living donor liver transplantation, HEPATOLOGY RESEARCH, 44巻, 12号, pp. 1259-1264, NOV 2014
  102. Efficacy and Safety of Sitagliptin for the Treatment of Nonalcoholic Fatty Liver Disease with Type 2 Diabetes Mellitus, HEPATO-GASTROENTEROLOGY, 61巻, 130号, pp. 323-328, MAR-APR 2014
  103. Percutaneous transvenous embolization for portosystemic shunts associated with encephalopathy: Long-term outcomes in 14 patients, HEPATOLOGY RESEARCH, 44巻, 7号, pp. 740-749, JUL 2014
  104. Human microRNA hsa-miR-1231 suppresses hepatitis B virus replication by targeting core mRNA, JOURNAL OF VIRAL HEPATITIS, 21巻, 9号, pp. E89-E97, 201409
  105. Non-invasive liver fibrosis score calculated by combination of virtual touch tissue quantification and serum liver functional tests in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 44巻, 3号, pp. 280-287, 201403
  106. Non-invasive assessment of liver steatosis in non-alcoholic fatty liver disease, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E420-E427, 201412
  107. Hepatitis C Virus Core Protein Suppresses Mitophagy by Interacting with Parkin in the Context of Mitochondrial Depolarization, AMERICAN JOURNAL OF PATHOLOGY, 184巻, 11号, pp. 3026-3039, 201411
  108. Impact of alloimmune T cell responses on hepatitis C virus replication in liver transplant recipients, HUMAN IMMUNOLOGY, 75巻, 12号, pp. 1259-1267, 201412
  109. Clinical outcome and prognostic factors of patients with hepatocellular carcinoma and extrahepatic metastasis treated with sorafenib, HEPATOLOGY RESEARCH, 44巻, 13号, pp. 1320-1328, 201412
  110. Interferon lambda 4 polymorphism affects on outcome of telaprevir, pegylated interferon and ribavirin combination therapy for chronic hepatitis C, HEPATOLOGY RESEARCH, 44巻, 14号, pp. E447-E454, DEC 2014
  111. Quantitative Effect of Natural Killer-Cell Licensing on Hepatocellular Carcinoma Recurrence after Curative Hepatectomy, CANCER IMMUNOLOGY RESEARCH, 2巻, 12号, pp. 1142-1147, DEC 2014
  112. Hepatitis C Virus (HCV) Reactivation Caused by Steroid Therapy for Dermatomyositis, INTERNAL MEDICINE, 53巻, 23号, pp. 2689-2693, 2014
  113. 直接作用型抗ウイルス薬に対する耐性変異, 日本臨床, 73巻, 2号, pp. 322-326, 2014
  114. 【ダクラタスビル・アスナプレビル併用療法】耐性関連変異と臨床成績, 肝・胆・膵, 69巻, pp. 322-326, 2014
  115. キメラマウスを用いたC型肝炎ウイルスに対するDAA薬剤の効果, 肝疾患Review 2014〜2015, pp. 95-99, 2014
  116. 【DAA(Direct Acting Antivirals)が変えるC型肝炎治療】薬剤耐性変異とその対策, BIO Clinica, 29巻, 3号, pp. 236-240, 2014
  117. IFN併用抗ウイルス療法とIFN-free抗ウイルス療法, 日本消化器病学会雑誌, 111巻, 9号, pp. 1747-1753
  118. C型慢性肝炎の最新治療, 日本内科学会雑誌, 103巻, 3号, pp. 625-629, 2014
  119. 消化器研究における最新技術ヒト肝細胞キメラマウスを用いたC型肝炎研究, G.I.Research, 22巻, 3号, pp. 282-288, 2014
  120. 近未来のIFN-feeDAA併用療法の展望, 医学と薬学, 71巻, 6号, pp. 989-993, 2014
  121. 難治例の治療戦略.DAAs併用療法, 医学のあゆみ別冊, 249巻, 3号, pp. 259-262, 2014
  122. HCV研究の最先端 肝ヒト化マウスを用いたHCV研究, 臨床消化器内科, 29巻, 7号, pp. 827-833, 2014
  123. DAAに対するウイルス耐性変異と対応法, Mebio, 31巻, 10号, pp. 38-42, 2014
  124. The effects of bisphosphonate zoledronic acid in hepatocellular carcinoma, depending on mevalonate pathway, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 3号, pp. 619-627, MAR 2015
  125. Effect of prolonged administration of pegylated interferon/ribavirin therapy in genotypes 2a and 2b: Propensity score-matched analysis, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 2号, pp. 337-344, FEB 2015
  126. Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection, SCIENCE TRANSLATIONAL MEDICINE, 7巻, 282号, APR 8 2015
  127. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 158-165, 201502
  128. Differences in serum microRNA profiles in hepatitis B and C virus infection, JOURNAL OF INFECTION, 70巻, 3号, pp. 273-287, MAR 2015
  129. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of Response Evaluation Criteria in Solid Tumors and tumor markers, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 30巻, 4号, pp. 726-732, APR 2015
  130. Ribavirin dose reduction during telaprevir/ribavirin/peg-interferon therapy overcomes the effect of the ITPA gene polymorphism, JOURNAL OF VIRAL HEPATITIS, 22巻, 2号, pp. 166-174, FEB 2015
  131. Two Patients Treated With Simeprevir Plus Pegylated-Interferon and Ribavirin Triple Therapy for Recurrent Hepatitis C After Living Donor Liver Transplantation: Case Report, TRANSPLANTATION PROCEEDINGS, 47巻, 3号, pp. 809-814, 201504
  132. Role of 3-D conformal radiotherapy for major portal vein tumor thrombosis combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 607-617, JUN 2015
  133. Disseminated carcinomatosis of the bone marrow originating from hepatocellular carcinoma. A case report, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 705-710, JUN 2015
  134. Efficacy and safety of the anticoagulant drug, danaparoid sodium, in the treatment of portal vein thrombosis in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 45巻, 6号, pp. 656-662, JUN 2015
  135. Rapid, Sensitive, and Accurate Evaluation of Drug Resistant Mutant (NS5A-Y93H) Strain Frequency in Genotype 1b HCV by Invader Assay, PLOS ONE, 10巻, 6号, JUN 17 2015
  136. Association between variants in the interferon lambda 4 locus and substitutions in the hepatitis C virus non-structural protein 5A, JOURNAL OF HEPATOLOGY, 63巻, 3号, pp. 554-563, SEP 2015
  137. ここまで変わったウイルス肝炎の治療 C型慢性肝炎 C型慢性肝炎に対するダクラタスビル/アスナプレビル療法, Medicina, 52巻, 2号, pp. 308-311, 201502
  138. 新世代のC型慢性肝炎治療薬, 最新医学, 70巻, 3号, pp. 436-441, 201503
  139. 【C型肝炎】ダクラタスビル・アスナプレビル併用療法の効果と注意点 , 消化器の臨床, 18巻, 1号, pp. 74-79, 201502
  140. DAA(direct-acting antivirals)に対する耐性変異 現状と実地診療, Medical Practice 3, 32巻, 3号, pp. 452-456, 201503
  141. ヒト肝細胞キメラマウスを用いた抗ウイルス薬薬効評価と臨床応用, 最新医学, 70巻, 9号, pp. 1756-1762, 201509
  142. 高齢者C型肝炎に対する抗ウイルス療法, 消化器内科, 58巻, 1号, pp. 66-71, 2014
  143. 新薬治療におけるC型肝炎ウイルス耐性変異と薬剤相互作用の問題に迫る, 内科, 113巻, 4号, pp. 709-712, 2014
  144. Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice, JOURNAL OF VIROLOGY, 89巻, 19号, pp. 10087-10096, 201510
  145. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy, JOURNAL OF MEDICAL VIROLOGY, 87巻, 11号, pp. 1913-1920, 201511
  146. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma, JOURNAL OF DIGESTIVE DISEASES, 16巻, 9号, pp. 505-512, SEP 2015
  147. Usefulness of combining gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for diagnosing the macroscopic classification of small hepatocellular carcinoma, EUROPEAN RADIOLOGY, 25巻, 11号, pp. 3272-3281, NOV 2015
  148. Sustained virological response to antiviral therapy improves survival rate in patients with recurrent hepatitis C virus infection after liver transplantation, HEPATOLOGY RESEARCH, 45巻, 11号, pp. 1047-1054, NOV 2015
  149. Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones, JOURNAL OF INFECTION, 72巻, 1号, pp. 91-102, JAN 2016
  150. ★, Elimination of HCV via a non-ISG-mediated mechanism by vaniprevir and BMS-788329 combination therapy in human hepatocyte chimeric mice, VIRUS RESEARCH, 213巻, pp. 62-68, 20160202
  151. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus, HEPATOLOGY RESEARCH, 46巻, 3号, pp. E146-E153, MAR 2016
  152. Development of hepatocellular carcinoma in patients with hepatitis C virus infection who achieved sustained virological response following interferon therapy: A large-scale, long-term cohort study, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 31巻, 5号, pp. 1009-1015, MAY 2016
  153. TRC8-dependent degradation of hepatitis C virus immature core protein regulates viral propagation and pathogenesis, NATURE COMMUNICATIONS, 7巻, MAY 2016
  154. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization, ANTICANCER RESEARCH, 36巻, 7号, pp. 3523-3529, JUL 2016
  155. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy, JOURNAL OF VIRAL HEPATITIS, 23巻, 9号, pp. 708-717, 201609
  156. ★, Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients, HEPATOLOGY RESEARCH, 46巻, 8号, pp. 758-764, 201607
  157. Improvement of renal dysfunction in a patient with hepatitis C virus-related liver cirrhosis by daclatasvir and asunaprevir combination therapy: A case report, HEPATOLOGY RESEARCH, 46巻, 9号, pp. 944-948, AUG 2016
  158. ★, Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: Case report, HEPATOLOGY RESEARCH, 46巻, 7号, pp. 707-712, 201606
  159. Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma, JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 40巻, 4号, pp. 524-530, JUL-AUG 2016
  160. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study, JOURNAL OF VIRAL HEPATITIS, 23巻, 11号, pp. 850-856, NOV 2016
  161. Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection, JOURNAL OF GASTROENTEROLOGY, 51巻, 11号, pp. 1073-1080, NOV 2016
  162. ★, Effects of ITPA polymorphism on decrease of hemoglobin during simeprevir, peg-interferon, and ribavirin combination treatment for chronic hepatitis C, HEPATOLOGY RESEARCH, 46巻, 12号, pp. 1256-1263, 201611
  163. ★, Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice, ANTIVIRAL THERAPY, 21巻, 4号, pp. 307-315, 2016
  164. Hepatitis C virus treatment update - A new era of all-oral HCV treatment, ADVANCES IN DIGESTIVE MEDICINE, 3巻, 4号, pp. 153-160, DEC 2016
  165. ★, Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing, JOURNAL OF INFECTIOUS DISEASES, 214巻, 11号, pp. 1687-1694, 20161201
  166. The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir plus asunaprevir, EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 11巻, 2号, pp. 103-113, 201702
  167. ★, Efficacy and Safety of Daclatasvir Plus Asunaprevir Therapy for Chronic Hepatitis C Patients With Renal Dysfunction, JOURNAL OF MEDICAL VIROLOGY, 89巻, 4号, pp. 665-671, 201704
  168. ★, Interferon alpha treatment stimulates interferon gamma expression in type I NKT cells and enhances their antiviral effect against hepatitis C virus, PLOS ONE, 12巻, 3号, 20170302
  169. The risk of transient postprandial oxyhypoglycemia in nonalcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 52巻, 2号, pp. 253-262, FEB 2017
  170. ★, The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients, JOURNAL OF GASTROENTEROLOGY, 52巻, 3号, pp. 366-375, 201703
  171. Quasispecies of Hepatitis C Virus Participate in Cell-Specific Infectivity, SCIENTIFIC REPORTS, 7巻, 20170322
  172. ★, Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 32巻, 3号, pp. 645-650, 201703
  173. ★, IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C, HEPATOLOGY RESEARCH, 47巻, 3号, pp. E5-E13, 201703
  174. Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases, HEPATOLOGY RESEARCH, 46巻, 13号, pp. 1402-1408, DEC 2016
  175. ★, Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52巻, 4号, pp. 504-511, 201704
  176. ★, ITPA polymorphism effects on decrease of hemoglobin during sofosbuvir and ribavirin combination treatment for chronic hepatitis C, JOURNAL OF GASTROENTEROLOGY, 52巻, 6号, pp. 746-753, 201706
  177. Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib, ONCOLOGY, 92巻, 6号, pp. 335-346, 2017
  178. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 6号, JUN 2017
  179. ★, Usefulness of humanized cDNA-uPA/SCID mice for the study of hepatitis B virus and hepatitis C virus virology, JOURNAL OF GENERAL VIROLOGY, 98巻, 5号, pp. 1040-1047, 201705
  180. Liver fibrosis assessment by FibroScan compared with pathological findings of liver resection specimen in hepatitis C infection, HEPATOLOGY RESEARCH, 47巻, 8号, pp. 767-772, JUL 2017
  181. The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy, PLOS ONE, 12巻, 8号, AUG 10 2017
  182. Aggressive angiomyxoma of the liver: a case report and literature review, SURGICAL CASE REPORTS, 3巻, AUG 23 2017
  183. Acute Graft Rejection and Formation of De Novo Donor-Specific Antibodies Triggered by Low Cyclosporine Levels and Interferon Therapy for Recurrent Hepatitis C Infection After Liver Transplantation: A Case Report, TRANSPLANTATION PROCEEDINGS, 49巻, 7号, pp. 1634-1638, SEP 2017
  184. Clinical outcome and prognostic factors in hepatocellular carcinoma patients with bone metastases medicated with zoledronic acid, HEPATOLOGY RESEARCH, 47巻, 10号, pp. 1053-1060, SEP 2017
  185. Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients, JOURNAL OF MEDICAL VIROLOGY, 89巻, 11号, pp. 1963-1972, NOV 2017
  186. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10巻, 2号, pp. 179-184, APR 2017
  187. Late-onset ornithine transcarbamylase deficiency associated with hyperammonemia, CLINICAL JOURNAL OF GASTROENTEROLOGY, 10巻, 4号, pp. 383-387, AUG 2017
  188. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury, JOURNAL OF GASTROENTEROLOGY, 52巻, 12号, pp. 1252-1257, DEC 2017
  189. Evaluation of antiviral effect of type I, II, and III interferons on direct-acting antiviral-resistant hepatitis C virus, ANTIVIRAL RESEARCH, 146巻, pp. 130-138, OCT 2017
  190. Serum HMGB1 concentrations at 4 weeks is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy, JOURNAL OF GASTROENTEROLOGY, 53巻, 1号, pp. 107-118, JAN 2018
  191. Characterization of Recombinant Flaviviridae Viruses Possessing a Small Reporter Tag, JOURNAL OF VIROLOGY, 92巻, 2号, JAN 2018
  192. Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis, HEPATOLOGY RESEARCH, 48巻, 1号, pp. 51-58, JAN 2018
  193. Clinical outcomes of stereotactic body radiotherapy for elderly patients with hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48巻, 2号, pp. 193-204, FEB 2018
  194. Involvement of Porphyromonas gingivalis in the progression of non-alcoholic fatty liver disease, JOURNAL OF GASTROENTEROLOGY, 53巻, 2号, pp. 269-280, FEB 2018
  195. Risk factors for exacerbation of gastroesophageal varices and portosystemic encephalopathy during treatment with nucleos(t)ide analogs for hepatitis B virus-related cirrhosis, HEPATOLOGY RESEARCH, 48巻, 4号, pp. 264-274, MAR 2018
  196. Efficacy and safety of ledipasvir/sofosbuvir with ribavirin in chronic hepatitis C patients who failed daclatasvir/asunaprevir therapy: pilot study, JOURNAL OF GASTROENTEROLOGY, 53巻, 4号, pp. 548-556, APR 2018
  197. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis, ONCOLOGY, 94巻, 4号, pp. 215-222, 2018
  198. Evaluation of glycemic variability in chronic liver disease patients with type 2 diabetes mellitus using continuous glucose monitoring, PLOS ONE, 13巻, 4号, APR 3 2018
  199. Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice, ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 61巻, 9号, SEP 2017
  200. HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients, PLOS ONE, 12巻, 12号, DEC 7 2017
  201. Prevalence of NS5A resistance associated variants in NS5A inhibitor treatment failures and an effective treatment for NS5A-P32 deleted hepatitis C virus in humanized mice, BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 500巻, 2号, pp. 152-157, JUN 2 2018
  202. Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection, JOURNAL OF INFECTIOUS DISEASES, 217巻, 11号, pp. 1761-1769, JUN 1 2018
  203. Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial, BMC CANCER, 18巻, JUN 4 2018
  204. Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure, JOURNAL OF GENERAL VIROLOGY, 99巻, 8号, pp. 1058-1065, AUG 2018
  205. Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics, HEPATOLOGY, 68巻, 2号, pp. 473-484, AUG 2018
  206. Clinical outcomes of sorafenib treatment failure for advanced hepatocellular carcinoma and candidates for regorafenib treatment in real-world practice, HEPATOLOGY RESEARCH, 48巻, 10号, pp. 814-820, SEP 2018
  207. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status, JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 33巻, 10号, pp. 1780-1786, OCT 2018
  208. Advanced liver fibrosis effects on the response to sofosbuvir-based antiviral therapies for chronic hepatitis C, JOURNAL OF MEDICAL VIROLOGY, 90巻, 12号, pp. 1834-1840, 201812
  209. Early experience of seven hepatocellular carcinoma cases treated with regorafenib, CLINICAL CASE REPORTS, 6巻, 11号, pp. 2217-2223, 201811
  210. CTL-associated and NK cell-associated immune responses induce different HBV DNA reduction patterns in chronic hepatitis B patients, JOURNAL OF VIRAL HEPATITIS, 25巻, 12号, pp. 1555-1564, 201812
  211. Endoplasmic reticulum-mediated induction of interleukin-8 occurs by hepatitis B virus infection and contributes to suppression of interferon responsiveness in human hepatocytes, VIROLOGY, 525巻, pp. 48-61, 201812
  212. Comparison of hepatic arterial infusion chemotherapy between 5-fluorouracil-based continuous infusion chemotherapy and low-dose cisplatin monotherapy for advanced hepatocellular carcinoma, HEPATOLOGY RESEARCH, 48巻, 13号, pp. 1118-1130, 201812
  213. The association between serum cytokine and chemokine levels and antiviral response by entecavir treatment in chronic hepatitis B patients, ANTIVIRAL THERAPY, 23巻, 3号, pp. 239-248, 2018
  214. The impact of interferon-free direct-acting antivirals on clinical outcome after curative treatment for hepatitis C virus-associated hepatocellular carcinoma: Comparison with interferon-based therapy, JOURNAL OF MEDICAL VIROLOGY, 91巻, 4号, pp. 650-658, 201904
  215. Real-world efficacy of glecaprevir plus pibrentasvir for chronic hepatitis C patient with previous direct-acting antiviral therapy failures, JOURNAL OF GASTROENTEROLOGY, 54巻, 3号, pp. 291-296, 201903
  216. Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis, HEPATOLOGY COMMUNICATIONS, 3巻, 3号, pp. 348-355, 201903
  217. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients: a pilot study, ANTIVIRAL THERAPY, 23巻, 8号, pp. 639-646, 2018
  218. HCV-Induced Epigenetic Changes Associated With Liver Cancer Risk Persist After Sustained Virologic Response, GASTROENTEROLOGY, 156巻, 8号, pp. 2313-+, 201906
  219. Circulating Tumor DNA Analysis for Liver Cancers and Its Usefulness as a Liquid Biopsy, CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, 1巻, 5号, pp. 516-534, 201509
  220. Comparison of intracellular responses between HBV genotype A and C infection in human hepatocyte chimeric mice, JOURNAL OF GASTROENTEROLOGY, 54巻, 7号, pp. 650-659, 201907
  221. Efficacy of glecaprevir and pibrentasvir treatment for genotype 1b hepatitis C virus drug resistance-associated variants in humanized mice, JOURNAL OF GENERAL VIROLOGY, 100巻, 7号, pp. 1123-1131, 201907
  222. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan, JOURNAL OF GASTROENTEROLOGY, 54巻, 8号, pp. 742-751, 201908
  223. Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt, CLINICAL JOURNAL OF GASTROENTEROLOGY, 12巻, 4号, pp. 341-346, 201908
  224. Correlation between Early Tumor Marker Response and Imaging Response in Patients with Advanced Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 97巻, 2号, pp. 75-81, 2019
  225. Management of HCV patients in cases of direct-acting antiviral failure, EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 13巻, 9号, pp. 839-848, 20190902
  226. Early changes in ammonia levels and liver function in patients with advanced hepatocellular carcinoma treated by lenvatinib therapy, SCIENTIFIC REPORTS, 9巻, 20190820
  227. Alcohol Use Disorders Identification Test-consumption Predicts the Risk of Excessive Alcohol Consumption After Liver Transplantation, TRANSPLANTATION PROCEEDINGS, 51巻, 6号, pp. 1934-1938, 2019
  228. Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis, BMC GASTROENTEROLOGY, 19巻, 1号, 20191024
  229. Regression of Idiopathic Thrombocytopenic Purpura in a Patient With Eradication of Hepatitis C Virus by Direct-Acting Antivirals, HEPATOLOGY, 71巻, 1号, pp. 389-391, 202001
  230. Hepatitis B virus-related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccination, HEPATOLOGY RESEARCH, 50巻, 2号, pp. 182-189, 202002
  231. Management of refractory ascites attenuates muscle mass reduction and improves survival in patients with decompensated cirrhosis, JOURNAL OF GASTROENTEROLOGY, 55巻, 2号, pp. 217-226, 202002
  232. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection, EUROPEAN JOURNAL OF RADIOLOGY, 124巻, 202003
  233. Successful retreatment with 12 weeks of glecaprevir and pibrentasvir for a genotype 2a HCV-infected hemodialysis patient who failed to respond to 8 weeks of prior glecaprevir and pibrentasvir therapy, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 2号, pp. 267-270, 202004
  234. Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection, INTERNAL MEDICINE, 59巻, 7号, pp. 941-944, 2020
  235. Comparative study on the replication of HCV1b genome between wild-type and cell culture-adaptive mutant in regard to sensitivities against anti-HCV drugs, MICROBIOLOGY AND IMMUNOLOGY, 64巻, 4号, pp. 296-303, 202004
  236. Skeletal Muscle Loss during Tyrosine Kinase Inhibitor Treatment for Advanced Hepatocellular Carcinoma Patients, LIVER CANCER, 9巻, 2号, pp. 148-155, 202004
  237. Isolated cardiac metastases of hepatocellular carcinoma after resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 3号, pp. 421-427, 202006
  238. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 12巻, 202005
  239. Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection, JOURNAL OF CLINICAL INVESTIGATION, 130巻, 6号, pp. 3205-3220, 20200601
  240. Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab, HEPATOLOGY RESEARCH, 50巻, 7号, pp. 885-888, 202007
  241. Tumor Fibroblast Growth Factor Receptor 4 Level Predicts the Efficacy of Lenvatinib in Patients With Advanced Hepatocellular Carcinoma, CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 11巻, 202005
  242. Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 5号, pp. 867-872, 202010
  243. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 5号, pp. 839-843, 202010
  244. Liver fibrosis assessments using FibroScan, virtual-touch tissue quantification, the FIB-4 index, and mac-2 binding protein glycosylation isomer levels compared with pathological findings of liver resection specimens in patients with hepatitis C infection, BMC GASTROENTEROLOGY, 20巻, 1号, 20200925
  245. Trends in Hepatic Functional Reserve of Patients with Hepatocellular Carcinoma Treated with Tyrosine Kinase Inhibitors, ONCOLOGY, 98巻, 10号, pp. 727-733, 202010
  246. Modeling-Based Response-Guided Glecaprevir-Pibrentasvir Therapy for Chronic Hepatitis C to Identify Patients for Ultrashort Treatment Duration, JOURNAL OF INFECTIOUS DISEASES, 222巻, 7号, pp. 1165-1169, 20201001
  247. Impact of viral eradication by direct-acting antivirals on the risk of hepatocellular carcinoma development, prognosis, and portal hypertension in hepatitis C virus-related compensated cirrhosis patients, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1222-1233, 202011
  248. Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib, ONCOLOGY, 98巻, 11号, pp. 787-797, 202011
  249. Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion, NATURE MICROBIOLOGY, 5巻, 12号, pp. 1532-+, 202012
  250. Real-word efficacy of sofosbuvir, velpatasvir plus ribavirin therapy for chronic hepatitis patients who failed to prior DAA therapy with NS5A-P32 deletion mutated HCV infection, CLINICAL JOURNAL OF GASTROENTEROLOGY, 13巻, 6号, pp. 1233-1238, 202012
  251. Real-world efficacy of sofosbuvir plus velpatasvir therapy for patients with hepatitis C virus-related decompensated cirrhosis, HEPATOLOGY RESEARCH, 50巻, 11号, pp. 1234-1243, 202011
  252. PNPLA3andHLA-DQB1polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication, JOURNAL OF GASTROENTEROLOGY, 55巻, 12号, pp. 1162-1170, 202012
  253. Abatacept treatment for patients with severe acute hepatitis caused by hepatitis B virus infection-Pilot study, JOURNAL OF VIRAL HEPATITIS, 28巻, 2号, pp. 400-409, 202102
  254. Establishment of a novel hepatitis B virus culture system using immortalized human hepatocytes, SCIENTIFIC REPORTS, 10巻, 1号, 20201210
  255. Signal Activation of Hepatitis B Virus-Related Hepatocarcinogenesis by Up-regulation of SUV39h1, JOURNAL OF INFECTIOUS DISEASES, 222巻, 12号, pp. 2061-2070, 20201215

著書等出版物

  1. 2005年07月, 慢性肝炎治療薬の選び方と使い方 , 南江堂, 2005年, 07, 単行本(一般書), 編著, 茶山 一彰 大石和佳 今村 道雄 , 137
  2. 2005年04月, B.検査と診断の基本を学ぶ/一般検査;血液検査/肝炎ウイルスマーカー, 講義録 消化器学;メディカルレビュー, 2005年, 04, 単行本(学術書), 共著, 今村 道雄 茶山 一彰 , 60
  3. 2006年04月, 4.B型重症、劇症肝炎 , 治療シリーズ1 肝臓病の最新治療;編集主幹:戸田剛太郎・沖田極・門田守人 編集委員:井廻道夫・幕内雅敏・恩地森一・森正樹・茶山一彰・持田智・銭谷幹男 株)寺田国際事務所/先端医療技術研究所, 2006年, 04, 単行本(学術書), 共著, 今村 道雄 , 140

招待講演、口頭・ポスター発表等

  1. C型慢性肝炎に対するDAA治療成績およびSVR後の肝発癌, 第43回西部肝臓学会, 2019年12月12日, 通常, 日本語
  2. C型慢性肝炎抗ウイルス療法における残された薬剤耐性の問題, 今村道雄, 第23回日本肝臓学会大会(JDDW), 2019年11月21日, 通常, 日本語, 神戸
  3. C型肝炎ウイルス感染マウスモデルを用いたNS5A-P32delおよびNS5B-S282T変異の検討, 20190531, 第55回日本肝臓学会総会, 2019年05月31日, 通常, 日本語, 日本肝臓学会
  4. DAA不成功C型慢性肝炎に対するマヴィレット再治療の成績およびマウスモデルを用いたグレカプレビルおよびピブレンタスビルの抗ウイルス効果、耐性変異の検討, 20190510, 第105回日本消化器病学会総会, 2019年05月10日, 通常, 日本語
  5. ヒト肝細胞移植マウスを用いたB型肝炎ウイルス感染後の血中ウイルス動態の検討, 20181215, 第5回Gプラス, 2018年12月15日, 通常, 日本語
  6. マウスモデルを用いたNS5A-P32欠失型HCVに対するDAA治療効果, 20181101, 第22回日本肝臓学会大会(JDDW), 2018年11月01日, 通常, 日本語, 日本肝臓学会, 神戸, 実験データ
  7. ヒト肝細胞キメラマウスを用いた肝炎ウイルス感染モデル, 今村 道雄, 第2回肝免疫ウイルスフロンティア, 2006年04月15日, 招待, 日本語
  8. C型慢性肝炎治療の現状と今後の展望, 第100回日本消化器病学会総会, 2014年04月26日, 通常, 日本語, 東京
  9. 肝移植後のC型肝炎ウイルス再感染に対する抗ウイルス療法の成績, 今村道雄, 第24回抗ウイルス療法研究会, 2014年05月09日, 通常, 日本語
  10. 肝移植後のC型肝炎ウイルス再感染に対する抗ウイルス療法の成績, 今村道雄, 第50回日本肝臓学会総会, 2014年05月25日, 通常, 日本語
  11. 第50回日本肝臓学会総会, 今村道雄, 第18回日本肝臓学会大会(JDDW), 2014年10月23日, 通常, 日本語
  12. 第18回日本肝臓学会大会(JDDW), The 11th JSH Single Topic Conference, 2014年11月20日, 招待, 英語
  13. C型慢性肝炎に対するプロテアーゼ阻害剤+NS5A阻害剤併用療法の治療効果, 今村道雄, 第101回日本消化器病学会総会, 2015年04月23日, 通常, 日本語
  14. C型慢性肝炎治療の現状と今後の展望, 今村道雄, 安芸地区医師会学術講演会, 2014年03月07日, 招待, 日本語
  15. C型慢性肝炎治療の今後の展望, 今村道雄, 安佐地区医師会第8回肝炎・肝癌地域連携バス研修会, 2014年04月11日, 招待, 日本語
  16. 安佐地区医師会第8回肝炎・肝癌地域連携バス研修会, 今村道雄, 赤十字血液シンポジウム, 2014年08月02日, 招待, 日本語
  17. C型肝炎の最新の治療, 今村道雄, 徳山市医師会学術講演会, 2014年08月08日, 招待, 日本語
  18. 徳山医師会, 今村道雄, みなとまちフォーラム, 2014年08月09日, 招待, 日本語
  19. C型慢性肝炎治療の現状と今後の展望, 今村道雄, 三原市医師会, 2014年08月21日, 招待, 日本語
  20. C型慢性肝炎に対する最新の治療, 今村道雄, 消化器病学会北海道地方会ランチョンセミナー, 2014年09月07日, 招待, 日本語
  21. C型肝炎の最新の治療, 佐伯クリニシャングループ学術講演会, 2014年09月10日, 招待, 日本語
  22. キメラマウスを用いた肝炎ウイルス研究, 信州培養細胞研究会, 2014年09月14日, 通常, 日本語
  23. 慢性肝炎の診断と治療, 2014年09月19日, 招待, 日本語
  24. C型肝炎の最新の治療, 山口市C型肝炎セミナー, 2014年09月26日, 招待, 日本語
  25. C型肝炎の最新の治療, 呉市医師会, 2014年10月03日, 招待, 日本語
  26. C型肝炎の最新の治療, 2014年10月07日, 招待, 日本語
  27. C型肝炎の最新の治療, 2014年11月04日, 招待, 日本語
  28. ヒト肝細胞キメラマウスを用いたウイルス性肝炎の病態解明と治療法開発, 2014年11月13日, 招待, 日本語
  29. HCV感染マウスを用いた DAAの治療効果および耐性ウイルスの検討, Hepatology Meeting in Japan 2014, 2014年11月22日, 招待, 日本語
  30. バニヘップ®製品プロファイルとC型肝炎治療の課題, バニプレビル発売記念講演会, 2014年12月06日, 招待, 日本語
  31. B型肝炎の病態と治療, Medical Tribuneウイルス肝炎セミナー, 2014年12月13日, 招待, 日本語
  32. C型慢性肝炎に対するテラプレビルの効果, C型肝炎学術講演会 〜テラプレビル 難治例への挑戦〜, 2015年01月24日, 招待, 日本語
  33. C型肝炎学術講演会 〜テラプレビル 難治例への挑戦〜, 朝倉・うきは会学術講演会, 2015年02月03日, 招待, 日本語
  34. C型慢性肝炎に対する新しい治療, 鳥取県東部医師会学術講演会, 2015年02月09日, 招待, 日本語
  35. C型慢性肝炎に対するDAA治療, Hepatology Meeting in Kyoto 2015, 2015年02月13日, 招待, 日本語
  36. 当院におけるC型慢性肝炎の肝線維化評価, 2015年03月04日, 招待, 日本語
  37. C型慢性肝炎治療の最新の話題〜新たな3剤併用療法を含めて〜, 2015年03月06日, 招待, 日本語
  38. C型慢性肝炎に対するDAA治療, 2015年03月12日, 招待, 日本語
  39. C型慢性肝炎治療の最新の話題〜新たな3剤併用療法を含めて〜, 神戸肝疾患治療研究会, 2015年03月14日, 招待, 日本語
  40. B型肝炎の治療および再活性化に対する対策, 第146回広島市薬剤師会生涯教育研修会, 2015年04月19日, 招待, 日本語
  41. B型およびC型肝炎の最新の治療-かかりつけ医と専門医のfollow upのしかた-, 2015年05月19日, 招待, 日本語
  42. C型慢性肝炎に対するDAA療法の現状と今後の展望, Sagami Liver Forum, 2015年06月02日, 招待, 日本語
  43. ダクラタスビル+アスナプレビル療法の治療効果および長期的肝線維化改善効果, 今村道雄, 第41回日本肝臓学会西部会, 2015年12月03日, 通常, 日本語
  44. 野生型および耐性型C型慢性肝炎に対するダクラタスビル+アスナプレビル療法の治療効果, 今村道雄, 第102回日本消化器病学会総会, 2016年04月21日, 通常, 日本語, 20160421
  45. C型慢性肝炎患者において,NS3/4Aプロテアーゼ阻害薬治療failureに出現したNS3-D168変異はdeep sequenceにより検出されなくなっても残存する, 今村道雄, 第26回抗ウイルス療法研究会, 2016年05月14日, 通常, 日本語, 20160514
  46. 薬剤耐性型C型慢性肝炎に対するダクラタスビル+アスナプレビル療法の治療効果およびプロテアーゼ阻害薬耐性変異の感受性, 今村道雄, 第52回日本肝臓学会総会, 2016年05月20日, 通常, 日本語
  47. Hepatitis B animal model using human hepatocyte chimeric mice, MICHIO IMAMURA, 2014年11月20日, 招待, 英語
  48. 2016年10月13日, 通常, 英語
  49. Genotype 2型C型慢性肝炎に対するソフォスブビル+リバビリン療法の効果および新規治療の探索, 第20回日本肝臓学会大会(JDDW), 2016年11月03日, 通常, 日本語
  50. C型慢性肝炎に対するソフォスブビルを用いた治療の効果と薬剤耐性変異の出現, 第53回日本肝臓学会総会, 2017年06月09日, 通常, 日本語
  51. Genotype 1型C型慢性肝炎に対するソホスブビル+レジパスビル療法およびダクラタスビル+アスナプレビル非SVR例に対するソホスブビル+レジパスビル+リバビリン療法の有効性の検討, 第21回日本肝臓学会大会(JDDW), 2017年10月13日, 通常, 日本語
  52. Genotype 1型C型慢性肝炎に対するDAA療法の効果と薬剤耐性変異の検討, 今村道雄, 第42回西部肝臓学会, 2017年12月17日, 通常, 日本語
  53. Genotype 1型C型慢性肝炎に対するDAA療法および今後問題となる症例の検討, 今村道雄, 第104回日本消化器病学会総会, 2018年04月19日, 通常, 日本語
  54. マウスモデルを用いたNS5A阻害薬高度耐性変異型HCVに対するdaclatasvir+asunaprevir+beclabuvirおよびgrecaprevir+pibrentasvir療法の検討, 第53回日本肝臓学会総会, 2018年06月14日, 通常, 日本語

受賞

  1. 2005年, 平成17年度Liver Forum in Kyoto研究助成奨励賞
  2. 2005年, 2005年度浜名湖シンポジウム研究奨励賞
  3. 2011年07月01日, 平成23年度Liver Forum in Kyoto研究奨励賞, ウイルス肝炎研究財団
  4. 2012年, 2012年度日本消化器病学会研究奨励賞

取得

  1. 特許権, 特許5152745, 2012年12月14日, HCV核酸配列
  2. 特許権, 5696317, 2015年02月20日, HCVの治療剤又は予防剤

外部資金

競争的資金等の採択状況

  1. 肝炎等克服実用化研究事業, HBV感染マウスを用いたHBVcccDNA制御に関する研究, 2015年04月01日, 2016年03月31日
  2. 肝炎等克服実用化研究事業, 感染マウスモデルによるHCV治療抵抗性および病原性の分子機構の解析, 2015年04月01日, 2016年03月31日
  3. 科学研究費助成事業(基盤研究(C)), DAA耐性型HCVに対する治療法の開発, 2014年, 2016年
  4. 科学研究費助成事業(基盤研究(C)), C 型慢性肝炎に対する IFN 治療における IL28B 多型とコア領域変異の影響, 2010年, 2012年
  5. 肝炎等克服実用化研究事業 , マウスモデルを用いたDAA治療と薬剤耐性変異の検討, 2016年04月01日, 2017年03月31日
  6. 肝炎等克服実用化研究事業 , HBV cccDNAの制御と排除を目指す新規免疫治療薬の開発, 2016年04月01日, 2017年03月31日
  7. 肝炎等克服実用化研究事業, 次世代シークエンス技術によるウイルス因子解析を基軸としたC型肝炎新規治療の病態解明と臨床応用  , 2016年, 2018年
  8. 肝炎等克服実用化研究事業, 多機能幹細胞を用いた自然免疫再構築による新規肝炎/肝癌治療法の開発, 2016年, 2018年
  9. 肝炎等克服実用化研究事業, C型肝炎ウイルス排除後の病態,生命予後.QOLに関する包括的研究, 2017年, 2019年
  10. 科学研究費助成事業(基盤研究(C)), B型肝炎ウイルス感染マウスを用いたゲノム編集によるHBVcccDNAの排除, 2017年, 2019年
  11. 肝炎等克服実用化研究事業 , マウスモデルを用いたDAA治療と薬剤耐性変異の検討, 2017年04月01日, 2018年03月31日
  12. 感染症実用化研究事業(肝炎等克服実用化研究事業) , マウスモデルを用いたDAA治療と薬剤耐性変異の検討, 2018年04月01日, 2019年03月31日
  13. 感染症実用化研究事業(肝炎等克服実用化研究事業) , マウスモデルを用いた変異型HCVの発現機構および肝病態への影響の検討 , 2019年04月01日, 2020年03月31日

社会活動

委員会等委員歴

  1. 日本肝臓学会評議員
  2. 日本消化器病学会評議員
  3. 客員研究員, 2016年04月, 2018年03月, 国立研究開発法人理化学研究所
  4. 非常勤医師, 2017年04月, 2018年03月, (医)たかまさ会山崎病院
  5. (医)JR広島病院, 2018年04月, 2019年03月, 非常勤医師
  6. 非常勤医師, 2019年04月, 2020年03月, (医)JR広島病院
  7. 非常勤医師, 2020年04月, 2021年03月, (医)JR広島病院
  8. 非常勤医師, 2020年04月, 2021年03月, (医)たかまさ会山崎病院

その他社会貢献活動(広大・部局主催含)

  1. ウイルス性肝炎, 日本肝臓学会, 日本肝臓学会市民公開講座, 2006年/05月/12日, 2006年/05月/12日, 講師
  2. 肝臓病基礎研究など, 広島大学, 弟2回広島肝臓プロジェクト研究センターシンポジウム, 2006年/06月/15日, 2006年/06月/15日, 編集

学術雑誌論文査読歴

  1. 2014年, Hepatology Research, 5
  2. 2014年, Journal of Gastroenterology, 2
  3. 2014年, Internal Medicine, 2
  4. 2014年, Clinical journal of Gastroenterology
  5. 2014年, Journal of Gastroenterol Hepatology, 1
  6. 2014年, 肝臓, 1